Seminars in Nephrology
Volume 29, Issue 2 , Pages 105-112 , March 2009

Kidney Disease Outcomes Quality Initiative Guidelines for Bone and Mineral Metabolism: Emerging Questions

  • Tejas V. Patel, MD, MPH
    • ,
  • Ajay K. Singh, MB

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ajay K. Singh, MB, FRCP (UK), Renal Division, Brigham and Women's Hospital, MRB-4, 75 Francis St, Boston, MA 02115

References 

  1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201
  2. Andress DL. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol. 2008;3:179–183
  3. Liddle J, Williamson M, Irwig L. Method for evaluating research and guideline evidence (MERGE). Sydney: New South Wales Department of Health; 1996;
  4. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490
  5. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110
  6. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl. 2005;94:S120–S127
  7. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  8. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  9. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004;8:54–58
  10. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 2005;16:507–513
  11. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68:1258–1266
  12. Gauci C, Moranne O, Fouqueray B, et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol. 2008;19:1592–1598
  13. Calvi LM, Bushinsky DA. When is it appropriate to order an ionized calcium?. J Am Soc Nephrol. 2008;19:1257–1260
  14. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–530
  15. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  16. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021
  17. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
  18. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441
  19. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  20. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
  21. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–965
  22. Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004;66:1239–1247
  23. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: chronic kidney disorders mineral and bone disease—calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol. 2008;3:168–173
  24. Winkelmayer WC, Tonelli M. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. Am J Kidney Dis. 2008;51:362–365
  25. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl. 2006;102:S29–S33
  26. Donadio C, Ardini M, Lucchesi A, Donadio E, Cantor T. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients (A possible indicator of bone turnover status?). Clin Nephrol. 2007;67:131–139
  27. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345–350
  28. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  29. Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int. 2006;70:931–937
  30. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345–1354
  31. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19:870–876
  32. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358–363
  33. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl. 1999;71:S238–S241
  34. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet. 1987;2:875–877
  35. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int. 2007;72:792–796
  36. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580
  37. Nemeth EF. Misconceptions about calcimimetics. Ann N Y Acad Sci. 2006;1068:471–476
  38. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  39. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467–476
  40. Valle C, Rodriguez M, Santamaria R, et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol. 2008;19:2430–2436
  41. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898–905
  42. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008;73:1355–1363
  43. Patel TV, Singh AK. Does treatment with calcitriol improve survival in predialysis patients with chronic kidney disease?. Nat Clin Pract Endocrinol Metab. 2008;4:484–485
  44. Martin K, Goldfarb S. Renal bone disease, disorders of divalent ions, and nephrolithiasis. NephSAP. 2008;7:302
  45. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab. 2008;26:66–72
  46. Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 2007;45:1498–1503
  47. Fujii N, Hamano T, Mikami S, et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant. 2007;22:1601–1607
  48. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation—a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2006;21:2275–2281
  49. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831
  50. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:2193–2203
  51. Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients?. Kidney Int. 2008;73:3–5
  52. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–2608
  53. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592
  54. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol. 2008;3:1555–1560

 Dr. Patel was supported by National Institutes of Health grant T32-DK07527-23.

PII: S0270-9295(09)00004-7

doi: 10.1016/j.semnephrol.2009.01.003

Seminars in Nephrology
Volume 29, Issue 2 , Pages 105-112 , March 2009

Article Tools